在小鼠中 Toll 样 7 受体激动剂诱导的α干扰素反应的药代动力学-药效学建模。
Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.
机构信息
Department of Pharmacokinetics, Pharmacodynamics and Metabolism, Pfizer Global Research and Development, Ramsgate Road, Sandwich, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2010 Mar;54(3):1179-85. doi: 10.1128/AAC.00551-09. Epub 2009 Dec 22.
Abstract
Recombinant alpha interferon (IFN-alpha) is used in the treatment of hepatitis C virus (HCV)-infected patients but is not optimal in terms of efficacy or tolerability. Toll-like 7 receptor (TLR-7) agonists stimulate the innate immune system to produce, among other cytokines, IFN-alpha and are being evaluated as alternative drugs to treat HCV infection. This paper describes the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling to understanding the behavior of a TLR-7 agonist [9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine (BHMA)] in mice, using IFN-alpha as a biomarker. This is the first report of such a PK-PD model, and the conclusions may be of utility in the clinical development of TLR-7 agonists for HCV infection.
摘要
重组α干扰素（IFN-α）用于治疗丙型肝炎病毒（HCV）感染患者，但在疗效和耐受性方面并不理想。 Toll 样受体 7 受体（TLR-7）激动剂可刺激先天免疫系统产生 IFN-α等细胞因子，并被评估为治疗 HCV 感染的替代药物。本文描述了应用药代动力学-药效学（PK-PD）模型来理解 TLR-7 激动剂[9-苄基-8-羟基-2-（2-甲氧基乙氧基）腺嘌呤（BHMA）]在小鼠中的行为，使用 IFN-α作为生物标志物。这是首次报道此类 PK-PD 模型，其结论可能对 TLR-7 激动剂治疗 HCV 感染的临床开发有用。
相似文献
1
Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.在小鼠中 Toll 样 7 受体激动剂诱导的α干扰素反应的药代动力学-药效学建模。
Antimicrob Agents Chemother. 2010 Mar;54(3):1179-85. doi: 10.1128/AAC.00551-09. Epub 2009 Dec 22.
2
Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.Toll 样受体 7（TLR-7）和 TLR-9 激动剂增强浆细胞样树突状细胞对丙型肝炎病毒复制和感染的抑制作用。
J Virol. 2018 Nov 12;92(23). doi: 10.1128/JVI.01219-18. Print 2018 Dec 1.
3
Activation of anti-hepatitis C virus responses via Toll-like receptor 7.通过Toll样受体7激活抗丙型肝炎病毒反应。
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1828-33. doi: 10.1073/pnas.0510801103. Epub 2006 Jan 30.
4
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.研究Toll样受体激动剂治疗丙型肝炎病毒感染的潜力。
Antimicrob Agents Chemother. 2007 Aug;51(8):2969-78. doi: 10.1128/AAC.00268-07. Epub 2007 Jun 4.
5
Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.比较不同干扰素制剂在 HIV/HCV 基因型 1 感染患者中的疗效、药代动力学、药效学活性和干扰素刺激基因表达。
J Med Virol. 2014 Feb;86(2):177-85. doi: 10.1002/jmv.23773. Epub 2013 Oct 26.
6
Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.新型 Toll 样受体 7 激动剂 GS-9620 的药代动力学和药效学特性表明，低口服剂量时即可诱导干扰素刺激基因表达，而血清干扰素水平可检测不到。
J Pharmacol Exp Ther. 2014 Jan;348(1):96-105. doi: 10.1124/jpet.113.207878. Epub 2013 Oct 16.
7
Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.干扰素-α抑制粒细胞集落刺激因子的产生可被 TLR7/8 激动剂 CL097 逆转。
J Gastroenterol Hepatol. 2010 Dec;25(12):1883-90. doi: 10.1111/j.1440-1746.2010.06281.x.
8
Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.聚乙二醇化干扰素α-2b治疗期间丙型肝炎病毒动力学建模：病毒动力学参数估计中的误差
J Viral Hepat. 2008 May;15(5):357-62. doi: 10.1111/j.1365-2893.2007.00954.x.
9
HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life.HM10660A，一种长效 hIFN-α-2b，通过增强生物半衰期成为治疗丙型肝炎的有力候选药物。
Int J Pharm. 2017 Dec 20;534(1-2):89-96. doi: 10.1016/j.ijpharm.2017.09.074. Epub 2017 Oct 2.
引用本文的文献
1
Mechanistic Evaluation of Anti-CD19 CAR-T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model.使用定量系统药理学模型对系统性红斑狼疮中重新利用的抗CD19 CAR-T细胞疗法进行机制评估。
Clin Transl Sci. 2025 Feb;18(2):e70146. doi: 10.1111/cts.70146.
2
Enteric Toll-like receptor 7 stimulation causes acute exacerbation in lupus-susceptible mice.肠 Toll 样受体 7 刺激导致狼疮易感小鼠的急性恶化。
Clin Rheumatol. 2023 Apr;42(4):1185-1194. doi: 10.1007/s10067-022-06467-7. Epub 2022 Dec 14.
3
89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model.89Zr-免疫 PET 显示抗 CD20-IFNα 融合蛋白在小鼠 B 细胞淋巴瘤模型中的治疗效果。
Mol Cancer Ther. 2022 Apr 1;21(4):607-615. doi: 10.1158/1535-7163.MCT-21-0732.
4
Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model.先天免疫在控制新冠病毒病病毒载量中起关键作用：来自全身感染动力学模型的机制性见解
ACS Pharmacol Transl Sci. 2020 Dec 30;4(1):248-265. doi: 10.1021/acsptsci.0c00183. eCollection 2021 Feb 12.
5
Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model.先天免疫在控制新冠病毒感染中的病毒载量方面起着关键作用：来自全身感染动力学模型的机制性见解
medRxiv. 2020 Nov 5:2020.10.30.20215335. doi: 10.1101/2020.10.30.20215335.
6
Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach.干扰素 α 给药的定量系统药理学：多尺度方法。
PLoS One. 2019 Feb 13;14(2):e0209587. doi: 10.1371/journal.pone.0209587. eCollection 2019.
7
A Type I Interferon and IL-10 Induced by Infection Suppresses Antigen-Specific T Cells and Their Memory Responses.感染诱导的 I 型干扰素和 IL-10 抑制抗原特异性 T 细胞及其记忆应答。
Front Immunol. 2018 Sep 4;9:2022. doi: 10.3389/fimmu.2018.02022. eCollection 2018.
8
Hepatitis C viral kinetics: the past, present, and future.丙型肝炎病毒动力学：过去、现在和未来。
Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003.
9
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Toll 样受体激动剂的药代动力学及其对免疫系统的影响。
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89. doi: 10.1586/ecp.11.5.
本文引用的文献
1
Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent.转化药代动力学-药效学模型；PF-00821385（一种新型 HIV 药物）心血管安全性数据的应用。
Br J Clin Pharmacol. 2010 Apr;69(4):336-45. doi: 10.1111/j.1365-2125.2009.03594.x.
2
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.将受体理论纳入基于机制的药代动力学-药效学（PK-PD）建模。
Drug Metab Pharmacokinet. 2009;24(1):3-15. doi: 10.2133/dmpk.24.3.
3
Residence time of receptor-ligand complexes and its effect on biological function.受体-配体复合物的驻留时间及其对生物学功能的影响。
Biochemistry. 2008 May 20;47(20):5481-92. doi: 10.1021/bi8002023. Epub 2008 Apr 16.
4
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.转化药物研究中基于机制的药代动力学-药效学（PK-PD）建模
Trends Pharmacol Sci. 2008 Apr;29(4):186-91. doi: 10.1016/j.tips.2008.01.007. Epub 2008 Mar 18.
5
The pharmacology of endosomal TLR agonists in viral disease.内体 Toll 样受体激动剂在病毒性疾病中的药理学。
Biochem Soc Trans. 2007 Dec;35(Pt 6):1468-72. doi: 10.1042/BST0351468.
6
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.研究Toll样受体激动剂治疗丙型肝炎病毒感染的潜力。
Antimicrob Agents Chemother. 2007 Aug;51(8):2969-78. doi: 10.1128/AAC.00268-07. Epub 2007 Jun 4.
7
Model-based drug development.基于模型的药物研发。
Clin Pharmacol Ther. 2007 Jul;82(1):21-32. doi: 10.1038/sj.clpt.6100235. Epub 2007 May 23.
8
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.丁丙诺啡药代动力学和药效学特性的动物到人外推法
Clin Pharmacokinet. 2007;46(5):433-47. doi: 10.2165/00003088-200746050-00005.
9
Toll-like receptors and Type I interferons.Toll样受体与I型干扰素。
J Biol Chem. 2007 May 25;282(21):15319-23. doi: 10.1074/jbc.R700009200. Epub 2007 Mar 29.
10
What's next in translational medicine?转化医学的下一步是什么？
Clin Sci (Lond). 2007 Feb;112(4):217-27. doi: 10.1042/CS20060108.
Zotero 插件